**Major Corporate Developments** Zhongnan Culture announced plans to acquire a 57.30% equity stake in Jiangyin Sulong Thermal Power Co., Ltd. from Jiangyin Electric Power Investment Co., Ltd. through a combination of share issuance and cash payment. The company also intends to raise supporting funds from no more than thirty-five specific investors. The auditing and evaluation work related to the transaction has not yet been completed, and the transaction plan requires further discussion and negotiation. This transaction is expected to constitute a significant asset restructuring. Upon completion, the listed company's business footprint in the electric power energy sector will be expanded. Additionally, the company will further leverage its strengths in industrial metal pipe fitting manufacturing to enhance sales expansion within the power sector, increase brand recognition and product market share, and further strengthen its machinery manufacturing business segment. Following an application to the Shenzhen Stock Exchange, the company's shares will resume trading on Monday, March 9, 2026.
GEM Co., Ltd. has entered into a strategic cooperation agreement with China ENFI Engineering Co., Ltd. The two parties will deepen strategic collaboration in the development of critical mineral resources, their green, low-carbon, and efficient utilization, and global layout. This agreement aims to enhance the global competitiveness of Chinese enterprises and provide solid support for safeguarding the strategic security of the nation's critical mineral resources, achieving technological self-reliance in key areas, and promoting high-quality development. The agreement is valid until December 31, 2030.
Haisco Pharmaceutical Group Company Limited announced that its subsidiary, Sichuan Haisco Pharmaceutical Co., Ltd., recently received an Acceptance Notice from the National Medical Products Administration for the marketing application of its innovative drug, HSK39297 Tablets. HSK39297 Tablets are indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). The drug is a small-molecule inhibitor of complement factor B (FB) independently developed by the company. It works by inhibiting FB activity to block the amplification loop of the complement system, thereby suppressing the activity of the entire complement pathway. Compared to eculizumab, HSK39297 Tablets demonstrate significant therapeutic advantages in improving anemia, reducing transfusion needs, and alleviating fatigue symptoms, with efficacy that can be maintained long-term. According to China's new chemical drug registration classification, this drug is classified as a Category 1 chemical drug.
Fengshang Culture announced that at the 15th meeting of its fourth board of directors held on March 7, 2026, the proposal to dismiss the company's Deputy General Manager, Li Yan, was reviewed and approved. Based on the operational management needs of the company and following review by the board's nomination committee, the board decided to remove Li Yan from the position of Deputy General Manager. Li Yan's original term was set to expire on August 1, 2027. The dismissal is effective from the date of the board's approval. Following the dismissal, Li Yan will no longer hold any position within the company. As of the date of this announcement, Li Yan does not hold any shares in the company and has no outstanding commitments.
Huasu Holdings issued a volatility announcement stating that its stock price had deviated by more than 20% over three consecutive trading days, constituting an abnormal trading fluctuation. The company's current primary business involves the R&D, design, production, and sales services of electronic information display terminals. The company's current production and operations are normal, with no significant changes to its main business. Its carbon emission governance business, as well as its precision machine tool manufacturing and sales business, are still in a developmental phase and account for a low proportion of overall operations. Investors are advised to be aware of risks and invest rationally.
Shandong Molong Petroleum Machinery Co., Ltd. issued a volatility announcement stating that its stock price had deviated by more than 20% over three consecutive trading days, constituting an abnormal trading fluctuation. Since March 2, 2026, the stock price had increased by 52.37% over five consecutive trading days, indicating risks associated with overheated market sentiment and irrational speculation. The company's current production and operational activities are normal. Fluctuations in international crude oil market prices currently have no substantive positive impact on the company's short-term performance. Investors are urged to make rational decisions, invest prudently, and be mindful of risks in the secondary market.
**Shareholding Changes** Fumiao Technology announced that its shareholder, Jiangsu Feixiang Chemical Co., Ltd., which holds more than 5% of shares, plans to reduce its holdings by no more than 2,864,893 shares via block trades, representing no more than 2.00% of the company's total shares. The reduction is due to the shareholder's own operational funding needs. The减持 will take place over a three-month period starting 15 trading days after the announcement date, specifically from March 31, 2026, to June 30, 2026.
Laplace announced that several shareholders collectively holding more than 5% of shares, including Rudong Hengjun, Sanya Hengjia, Rudong Ruida, and Rudong Jiada, plan to reduce their collective holdings by no more than 4,053,261 shares through centralized bidding, representing no more than 1% of the company's total shares. The减持 is due to the shareholders' own funding requirements. The减持 period will be three months starting 15 trading days after the announcement date. The减持 price will be determined based on market prices.
Hongbo New Materials announced that its shareholder, Xinyu Jinhong Technology Partnership, plans to reduce its holdings by no more than 2.3 million shares via centralized bidding, representing no more than 0.32% of the company's total shares. The减持 is due to the shareholder's own funding needs. The减持 will occur over a three-month period starting 15 trading days after the plan's disclosure date, specifically from March 31, 2026, to June 30, 2026.
Comments